Is Aurora Cannabis (TSX:ACB) a Steal at Under $10?

In light of the challenges faced by its main rival, there could be an opportunity for Aurora Cannabis Inc (TSX:ACB)(NYSE:ACB) to win back some investors it may have lost.

| More on:
Cannabis stocks have fallen.
You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

Investors haven’t been very bullish on marijuana stocks lately, and that could mean there might be some deals out there today. Aurora Cannabis (TSX:ACB)(NYSE:ACB) has seen only modest single-digit returns over the past year, as it has taken investors on a bit of a roller-coaster ride. However, with rival Canopy Growth (TSX:WEED)(NYSE:CGC) no longer having Bruce Linton to help steer the ship, it could be a great time to load up on Aurora’s stock. Let’s take a closer to look to see if it’s a good buy at around $10 or less.

Sales growth has been strong and not too far behind Canopy Growth

Over the past 12 months, Aurora’s sales have climbed to $168 million, and during that time the company has incurred losses of $211 million. However, in two of the past four quarters, Aurora has been able to stay in the black. In its most recent earnings report, the company benefited from $16 million in fair-value gains.

Canopy Growth, meanwhile, lost $685 million on sales of $226 million over the trailing 12 months. With about 34% more in sales than Aurora, the gap is not as big as the disparity in market cap would have you believe, as Canopy Growth often trades at more than double its valuation. Certainly, there are intangibles and other factors that drive up the value (like Canopy Growth being the industry leader and having some advantages, such as its strong brand and the personnel  it has involved with the company), but for the valuation to be more than double seems a bit high.

If we look at multiples to sales, Aurora trades at around 60 times the revenue it generated over the past year, while Canopy Growth is over 75. Both multiples are very high, but they suggest that Aurora may not be overpriced at all, especially in comparison to its strongest competitor.

Opportunity for Aurora to take advantage

Initially, having a partner like Constellation Brands gave Canopy Growth a big advantage over its peers — a partner with a lot of capital and the experience to help navigate the beverage segment certainly seemed like a big positive for the cannabis company. However, in light of recent events, it might be that Aurora is better off without a partner that might put pressure on its operations. Instead, Aurora has the potential to be more aggressive and take advantage of opportunities that Canopy Growth might now be more timid of, given its focus on improving profitability.

If Aurora takes a page out of Canopy Growth’s old playbook, it could be what the stock needs to get going to help show that the company is serious about being the top pot stock in the industry. If it does, it would certainly be a good deal at its current price.

Bottom line

There’s an opportunity for Aurora now to show to investors why it can be a better buy than Canopy Growth, and that’s going to be crucial in getting the markets excited about the stock. There’s definitely reason to believe that Aurora can rise in value from where it is today, but it’s going to need at least one big move to get the stock going again.  If you can buy the stock for under $10, it could prove to be a great buy.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor David Jagielski has no position in any of the stocks mentioned.

More on Cannabis Stocks

Cannabis smoke
Cannabis Stocks

Canopy Growth Stock: Is Now a Good Time to Invest?

The road ahead is highly uncertain for Canopy Growth, as the stock is plagued with losses and seemingly unsurmountable industry…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

TLRY Stock: Should You Invest Now?

TLRY is a Canadian cannabis stock which is trading 91% below record highs. Let's see if you should own TLRY…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is Tilray Stock a Buy in February 2023?

Despite the volatile cannabis sector, Tilray could be a superb buy for long-term investors.

Read more »

Young woman sat at laptop by a window
Cannabis Stocks

Is SNDL Stock a Buy in February 2023?

SNDL is a beaten-down cannabis stock. While its revenue growth is exceptional, a weak balance sheet has driven stock prices…

Read more »

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »